That last big DD I wrote in this forum was RDW, which has since rallied almost 200% from lows and RKLB when it was <$5.
Whilst I see this play carries a little more risk it’s something that now has a lot more potential thanks to the recent grant, given the bear case was the company heading for bankruptcy.
For those unaware of what or who Evogene is, they’re an Israeli AI company that’s been going since 2002. Their idea was to build custom AI software to speed up the innovation and reduce the cost to market of new products. To do this they created 4 subsidiaries which would work independently from each other yet remain under the same umbrella.
Whilst the company has backing from major players and contracts with Fortune 500 companies, it’s market cap now sits at $10m which is the same as their most recent capital injection from an Angel investor in Shenzhen.
They have one commercial product that they’ve only just started to roll out yet to great success which are their castor seeds, a genetically modified strain produced by their in house AI model. Rather than regurgitate facts take a read of their latest presentation
https://evogene.com/wp-content/uploads/2024/09/Casterra_Company_presentation_Sep_2024_FINAL.pdf
Next up, Biomeca (https://www.biomicamed.com)
View their current pipeline here https://www.biomicamed.com/pipeline/
Then we have LavieBio, where once again they have their first commercial product and it’s the same company which just received a grant to bring it’s second to the market.
Company Presentation: https://evogene.com/wp-content/uploads/2024/06/Lavie_Bio_company_presentation_June_2024_FINAL.pdf
Leave a Reply